Tackling Multi-Drug Resistant Bacteria By Dr Ankit Mahadevia Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such… Read More
Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a… Read More
Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing By Dr Maureen Bunger With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its… Read More
Long-Read Sequencing Offers Path to More Accurate Drug Metabolism Profiles By Dr Jenny Ekholm In the complex drug discovery process, one of the looming questions for any new compound is how it will be metabolised in a human body. While there are several methods for evaluating this,… Read More
UX Design – Maximising the Value of Scientific Software in Life Science R&D By Dr Jennifer A. Cham & Katrina Costa Using scientific software can be frustrating and time-consuming, resulting in less productive research. This article aims to demonstrate that User Experience (UX) Design – an evidence-based design… Read More
3D Cell Culture – A Rapidly Emerging Technique for Drug Discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a… Read More
Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition By Guy Webber Intelligent application of early in vitro testing can help mitigate major drug development risks. The pharmaceutical industry is inherently risky. To develop a molecule that has a desired,… Read More
Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. Read More
A Marriage of Technologies for Immuno-Oncology In Vivo Studies By Dr Philip Dube Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery… Read More
Spheroids Rapidly Becoming a Preferred 3D Cell Culture Format By Dr John Comley There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D cell culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they… Read More
The Discoverome – Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly… Read More
Immuno-Oncology’s Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond… Read More
Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and… Read More
A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater… Read More
Automated Liquid Handler Vendor vs Third Party Plastic Company by Dr John Comley Competing for the disposable pipette tip business. Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a ‘compatible’ product from a third… Read More
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers… Read More
